Zoetis Inc. (NYSE:ZTS) Stock Position Lowered by Sound View Wealth Advisors Group LLC

Sound View Wealth Advisors Group LLC lessened its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 43.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 8,904 shares of the company's stock after selling 6,773 shares during the quarter. Sound View Wealth Advisors Group LLC's holdings in Zoetis were worth $1,451,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ZTS. Mizuho Securities USA LLC increased its stake in Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock valued at $950,524,000 after buying an additional 4,829,815 shares during the period. Raymond James Financial Inc. acquired a new position in Zoetis in the 4th quarter valued at approximately $196,651,000. Amundi increased its stake in shares of Zoetis by 46.2% during the 4th quarter. Amundi now owns 2,748,719 shares of the company's stock worth $453,355,000 after purchasing an additional 867,993 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Zoetis by 296.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company's stock worth $144,917,000 after purchasing an additional 665,331 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company's stock worth $336,266,000 after purchasing an additional 572,511 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

NYSE:ZTS opened at $170.34 on Monday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The firm's fifty day simple moving average is $166.72 and its 200 day simple moving average is $176.74. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $76.28 billion, a PE ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94.

Remove Ads

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is presently 36.56%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company's stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ZTS. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday. Morgan Stanley dropped their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Finally, Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price target on the stock. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.